AGT and diabetes mellitus: In trials such as Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) [33], the Study on Cognition and Prognosis in the Elderly (SCOPE) [34], the Jikei Heart Study [35], and Action in Diabetes and Vascular Disease (ADVANCE) [36], the use of other antihypertensive agents was greater in the placebo group, leading to a likely underestimation of the underlying effect of the trial treatment, and the possibility of missing effects on some outcomes.